Measuring the Activated Clotting Time in patients receiving unfractionated heparin prior to coronary angiography and intervention. A single-centre validation study comparing different blood sampling sites - Validation of ACT measurements

Medisch Centrum Alkmaar0 个研究点目标入组 100 人开始时间: 待定最近更新: 2024年2月28日

试验速览

暂无简介。

•Consecutive patients scheduled for diagnostic coronary angiography or elective percutaneous coronary intervention (PCI) are screened for entry into this study. Patient are eligible for this study when it is expected that the scheduled procedure will be accomplished with a single bolus of heparin, i.e. patient undergoing a procedure with expected duration of > 1 hour will not be included in this study.

•- Use of novel oral anticoagulants or vitamin K antagonists
•- Chronic use of non-steroid anti-inflammatory drugs with the exception of aspirin
•- Known renal insufficiency (e.g. serum creatinine level of more than 265 *mol/L (i.e. more than 3.5 mg/L))
•- Liver function disorders with coagulopathies (PT >1.5N, INR >2.0 and/or thrombocyte count < 100 x 109/L)
•- Suspicion of unstable coronary artery disease with chest pain in rest, ECG changes, elevated cardiac markers, or hemodynamic instability at the time of the procedure
•- Serious known concomitant disease with a life expectancy of less than one year
•- Unability to read and understand the Dutch language
•- Previous participation in this study

发起方

Medisch Centrum Alkmaar